These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 16731829)

  • 1. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms.
    Okada T; Wada J; Hida K; Eguchi J; Hashimoto I; Baba M; Yasuhara A; Shikata K; Makino H
    Diabetes; 2006 Jun; 55(6):1666-77. PubMed ID: 16731829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Galectin-9 inhibits glomerular hypertrophy in db/db diabetic mice via cell-cycle-dependent mechanisms.
    Baba M; Wada J; Eguchi J; Hashimoto I; Okada T; Yasuhara A; Shikata K; Kanwar YS; Makino H
    J Am Soc Nephrol; 2005 Nov; 16(11):3222-34. PubMed ID: 16177004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.
    Ko GJ; Kang YS; Han SY; Lee MH; Song HK; Han KH; Kim HK; Han JY; Cha DR
    Nephrol Dial Transplant; 2008 Sep; 23(9):2750-60. PubMed ID: 18388116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes.
    Rüster C; Bondeva T; Franke S; Förster M; Wolf G
    Nephrol Dial Transplant; 2008 Jul; 23(7):2179-91. PubMed ID: 18344241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of high glucose and PPAR-gamma agonists on PPAR-gamma expression and function in HK-2 cells.
    Panchapakesan U; Pollock CA; Chen XM
    Am J Physiol Renal Physiol; 2004 Sep; 287(3):F528-34. PubMed ID: 15113752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts.
    Zafiriou S; Stanners SR; Saad S; Polhill TS; Poronnik P; Pollock CA
    J Am Soc Nephrol; 2005 Mar; 16(3):638-45. PubMed ID: 15689403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parathyroid hormone-related protein induces hypertrophy in podocytes via TGF-beta(1) and p27(Kip1): implications for diabetic nephropathy.
    Romero M; Ortega A; Izquierdo A; López-Luna P; Bosch RJ
    Nephrol Dial Transplant; 2010 Aug; 25(8):2447-57. PubMed ID: 20200004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor-δ activation ameliorates albuminuria by preventing nephrin loss and restoring podocyte integrity in type 2 diabetes.
    Lee EY; Kim GT; Hyun M; Kim S; Seok S; Choi R; Lee MY; Chung CH
    Nephrol Dial Transplant; 2012 Nov; 27(11):4069-79. PubMed ID: 22892126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Troglitazone inhibits synthesis of transforming growth factor-beta1 and reduces matrix production in human peritoneal mesothelial cells.
    Peng Y; Liu H; Liu F; Liu Y; Li J; Chen X
    Nephrology (Carlton); 2006 Dec; 11(6):516-23. PubMed ID: 17199790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
    Calkin AC; Giunti S; Jandeleit-Dahm KA; Allen TJ; Cooper ME; Thomas MC
    Nephrol Dial Transplant; 2006 Sep; 21(9):2399-405. PubMed ID: 16720596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
    Lin MS; Chen WC; Bai X; Wang YD
    J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
    Cha DR; Zhang X; Zhang Y; Wu J; Su D; Han JY; Fang X; Yu B; Breyer MD; Guan Y
    Diabetes; 2007 Aug; 56(8):2036-45. PubMed ID: 17536062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated-gamma-ligand, in insulin-deficient diabetic rats.
    Yamagishi S; Ogasawara S; Mizukami H; Yajima N; Wada R; Sugawara A; Yagihashi S
    J Neurochem; 2008 Jan; 104(2):491-9. PubMed ID: 17995925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency.
    Wolf G; Schanze A; Stahl RA; Shankland SJ; Amann K
    Kidney Int; 2005 Oct; 68(4):1583-9. PubMed ID: 16164635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
    Katavetin P; Eiam-Ong S; Suwanwalaikorn S
    J Med Assoc Thai; 2006 Feb; 89(2):170-7. PubMed ID: 16579002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor.
    Russo LM; del Re E; Brown D; Lin HY
    Diabetes; 2007 Feb; 56(2):380-8. PubMed ID: 17259382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model.
    Kim SK; Zhao ZS; Lee YJ; Lee KE; Kang SM; Choi D; Lim SK; Chung N; Lee HC; Cha BS
    Diabetes Metab Res Rev; 2003; 19(6):487-93. PubMed ID: 14648808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta.
    Toba H; Miki S; Shimizu T; Yoshimura A; Inoue R; Sawai N; Tsukamoto R; Murakami M; Morita Y; Nakayama Y; Kobara M; Nakata T
    Eur J Pharmacol; 2006 Nov; 549(1-3):124-32. PubMed ID: 16979161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on ischemia-reperfusion injury in rats.
    Cao Z; Ye P; Long C; Chen K; Li X; Wang H
    Pharmacology; 2007; 79(3):184-92. PubMed ID: 17356310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer.
    Shigeto T; Yokoyama Y; Xin B; Mizunuma H
    Oncol Rep; 2007 Oct; 18(4):833-40. PubMed ID: 17786343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.